Stock listing
Stuttgart:41O Outlook Therapeutics, Inc. Aktie
German listing (Stuttgart) of Outlook Therapeutics, Inc. · home listing NASDAQ:OTLK
Follow Outlook Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:OTLK
$0.493 USD +0.005 (+1.0%)
Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:OTLK
- Day range
- $0.481 – $0.522 USDOct 19, 2026
- Volume
- 2.61M sharesOct 19, 2026
- Market cap
- $120.1M USDAt the close on Oct 19, 2026 · price × 243.5M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:OTLK · Home | $0.493 USD | +0.005 (+1.0%) | 2,605,147 | $0.491 | $0.522 | $0.481 | $0.488 | Close on Oct 19, 2026 |
| Frankfurt:41O | €0.449 EUR | +0.016 (+3.8%) | 2,000 | €0.431 | €0.449 | €0.423 | €0.433 | Close on Oct 19, 2026 |
Daily closes
Last 3 months, Jul 20, 2026 – Oct 19, 2026 · NASDAQ:OTLK · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.493 | +0.005 | +1.0% | $0.491 | $0.522 | $0.481 | 2,605,147 | |
| $0.488 | -0.012 | -2.4% | $0.520 | $0.533 | $0.485 | 3,087,236 | |
| $0.500 | +0.030 | +6.3% | $0.488 | $0.510 | $0.438 | 5,324,746 | |
| $0.470 | -0.094 | -16.6% | $0.557 | $0.565 | $0.470 | 9,512,996 | |
| $0.564 | -0.021 | -3.6% | $0.579 | $0.581 | $0.551 | 3,241,332 | |
| $0.585 | -0.014 | -2.3% | $0.599 | $0.600 | $0.570 | 2,291,750 | |
| $0.599 | +0.035 | +6.2% | $0.568 | $0.605 | $0.556 | 3,685,016 | |
| $0.564 | -0.026 | -4.4% | $0.580 | $0.590 | $0.551 | 4,002,270 | |
| $0.590 | +0.018 | +3.1% | $0.602 | $0.607 | $0.580 | 4,235,060 | |
| $0.572 | -0.024 | -4.0% | $0.600 | $0.620 | $0.572 | 3,164,200 | |
| $0.596 | +0.003 | +0.5% | $0.600 | $0.610 | $0.580 | 4,687,700 | |
| $0.593 | +0.018 | +3.1% | $0.590 | $0.607 | $0.572 | 5,619,600 | |
| $0.575 | +0.001 | +0.2% | $0.580 | $0.590 | $0.531 | 7,068,800 | |
| $0.574 | -0.052 | -8.3% | $0.626 | $0.635 | $0.573 | 9,011,700 | |
| $0.626 | +0.005 | +0.8% | $0.630 | $0.636 | $0.612 | 4,583,100 | |
| $0.621 | -0.019 | -3.0% | $0.630 | $0.638 | $0.601 | 6,095,600 | |
| $0.640 | -0.016 | -2.4% | $0.655 | $0.671 | $0.636 | 2,927,700 | |
| $0.656 | -0.006 | -0.9% | $0.660 | $0.680 | $0.641 | 2,780,200 | |
| $0.662 | -0.034 | -4.9% | $0.705 | $0.705 | $0.662 | 2,928,400 | |
| $0.696 | +0.010 | +1.5% | $0.686 | $0.714 | $0.677 | 2,855,000 | |
| $0.686 | +0.033 | +5.1% | $0.685 | $0.695 | $0.653 | 2,877,700 | |
| $0.653 | -0.028 | -4.1% | $0.700 | $0.700 | $0.653 | 5,622,000 | |
| $0.681 | +0.004 | +0.6% | $0.695 | $0.710 | $0.678 | 2,804,600 | |
| $0.677 | +0.004 | +0.6% | $0.675 | $0.736 | $0.662 | 7,315,300 | |
| $0.673 | +0.035 | +5.5% | $0.640 | $0.682 | $0.625 | 4,508,500 | |
| $0.638 | -0.022 | -3.3% | $0.654 | $0.669 | $0.632 | 2,839,000 | |
| $0.660 | -0.001 | -0.2% | $0.670 | $0.680 | $0.650 | 3,327,800 | |
| $0.661 | +0.017 | +2.6% | $0.635 | $0.670 | $0.626 | 3,112,000 | |
| $0.644 | +0.003 | +0.5% | $0.640 | $0.645 | $0.621 | 2,672,000 | |
| $0.641 | -0.026 | -3.9% | $0.658 | $0.670 | $0.633 | 4,805,600 | |
| $0.667 | +0.018 | +2.8% | $0.660 | $0.696 | $0.645 | 6,395,700 | |
| $0.649 | +0.023 | +3.7% | $0.622 | $0.665 | $0.617 | 6,640,800 | |
| $0.626 | +0.003 | +0.5% | $0.620 | $0.640 | $0.604 | 4,607,300 | |
| $0.623 | -0.010 | -1.6% | $0.630 | $0.641 | $0.615 | 3,579,900 | |
| $0.633 | -0.012 | -1.9% | $0.631 | $0.664 | $0.628 | 6,423,800 | |
| $0.645 | +0.004 | +0.6% | $0.650 | $0.659 | $0.619 | 9,486,900 | |
| $0.641 | +0.018 | +2.9% | $0.643 | $0.675 | $0.636 | 6,853,300 | |
| $0.623 | -0.017 | -2.7% | $0.640 | $0.659 | $0.623 | 6,063,200 | |
| $0.640 | +0.031 | +5.1% | $0.615 | $0.685 | $0.612 | 15,948,640 | |
| $0.609 | -0.038 | -5.9% | $0.622 | $0.641 | $0.590 | 14,797,360 | |
| $0.647 | -0.029 | -4.3% | $0.676 | $0.706 | $0.640 | 11,497,100 | |
| $0.676 | -0.014 | -2.0% | $0.690 | $0.716 | $0.665 | 8,670,000 | |
| $0.690 | -0.010 | -1.4% | $0.708 | $0.718 | $0.671 | 20,760,400 | |
| $0.700 | +0.028 | +4.2% | $0.672 | $0.704 | $0.602 | 41,041,300 | |
| $0.672 | -0.084 | -11.1% | $0.795 | $0.798 | $0.670 | 80,658,300 | |
| $0.756 | -0.133 | -15.0% | $0.844 | $0.844 | $0.712 | 104,623,200 | |
| $0.889 | -0.211 | -19.2% | $0.769 | $0.892 | $0.760 | 82,392,900 | |
| $1.100 | -0.030 | -2.7% | $1.120 | $1.180 | $1.070 | 8,070,100 | |
| $1.130 | -0.020 | -1.7% | $1.150 | $1.158 | $1.090 | 6,090,400 | |
| $1.150 | +0.130 | +12.7% | $1.000 | $1.180 | $0.995 | 10,314,200 | |
| $1.020 | +0.047 | +4.8% | $0.986 | $1.040 | $0.950 | 4,560,300 | |
| $0.973 | -0.057 | -5.5% | $1.000 | $1.060 | $0.973 | 3,976,100 | |
| $1.030 | +0.070 | +7.3% | $0.950 | $1.040 | $0.941 | 5,197,000 | |
| $0.960 | +0.047 | +5.1% | $0.910 | $0.998 | $0.840 | 14,491,700 | |
| $0.913 | -0.064 | -6.6% | $0.965 | $0.975 | $0.900 | 5,993,500 | |
| $0.977 | -0.063 | -6.1% | $1.010 | $1.035 | $0.928 | 8,191,300 | |
| $1.040 | +0.040 | +4.0% | $1.020 | $1.060 | $0.965 | 9,921,200 | |
| $1.000 | +0.096 | +10.6% | $0.885 | $1.120 | $0.883 | 28,546,600 | |
| $0.904 | -0.161 | -15.1% | $1.010 | $1.015 | $0.820 | 34,871,100 | |
| $1.065 | -0.340 | -24.2% | $1.420 | $1.420 | $1.040 | 40,412,100 | |
| $1.405 | +0.085 | +6.4% | $1.350 | $1.750 | $1.120 | 57,886,700 | |
| $1.320 | -0.020 | -1.5% | $1.320 | $1.345 | $1.260 | 6,069,000 | |
| $1.340 | -0.080 | -5.6% | $1.410 | $1.410 | $1.300 | 8,411,900 | |
| $1.420 | +0.040 | +2.9% | $1.420 | $1.455 | $1.380 | 4,145,276 | |
| $1.380 | -0.010 | -0.7% | $1.420 | $1.520 | $1.365 | 7,079,087 |
- Ticker
- Stuttgart:41O
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Oct 9, 2026
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Latest earnings call · Aug 14, 2026
Outlook Therapeutics (NASDAQ:OTLK) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 14, 2026
Q3 2026 Earnings Presentation
Earnings · 16 slides
Calls
Replays
Outlook Therapeutics (NASDAQ:OTLK) Q3 2026 Earnings Call
Fri, Aug 14, 2026 · 8:30 AM ET
Watch TranscriptOutlook Therapeutics (NASDAQ:OTLK) Q3 2024 Earnings Call
Wed, Aug 14, 2024 · 8:30 AM ET
Watch TranscriptOutlook Therapeutics (NASDAQ:OTLK) Q2 2024 Earnings Call
Thu, May 16, 2024 · 8:30 AM ET
Watch Transcript
Latest news
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Oct 9, 2026
Closed $0.599 (+6.2%) on Oct 9, 2026
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
Oct 6, 2026
Closed $0.572 (-4.0%) on Oct 6, 2026
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Oct 1, 2026
Closed $0.575 (+0.2%) on Oct 1, 2026
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Sep 11, 2026
Closed $0.66 (-0.2%) on Sep 11, 2026
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Sep 10, 2026
Closed $0.661 (+2.6%) on Sep 10, 2026
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Aug 27, 2026
Closed $0.641 (+2.9%) on Aug 27, 2026
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Aug 14, 2026
Closed $0.756 (-15.0%) on Aug 14, 2026
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
Aug 12, 2026
Closed $0.889 (-19.2%) on Aug 13, 2026
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Aug 12, 2026
Closed $0.889 (-19.2%) on Aug 13, 2026
Outlook Therapeutics Secures FDA Approval For LYTENAVA™
Aug 5, 2026
Closed $1.03 (+7.3%) on Aug 5, 2026
Financings
Public offering of common stock and accompanying warrants
Aug 13, 2026
Update: about US$55M · US$0.99 a share · Warrants at US$1.1 for 60 months · Piper Sandler +2
Dealers: Piper Sandler (co-lead), BTIG (co-lead), Brookline Capital Markets, a division of Arcadia Securities, LLC
Use of proceeds: Support the US commercial launch of LYTENAVA, working capital and general corporate purposes
Decks
Q3 2026 Earnings Presentation
Earnings · 16 slides · Aug 14, 2026
Technical Presentation (January 2025)
Technical · 13 slides · January 2025
Corporate Update (August 2021)
Corporate update · 21 slides · Aug 3, 2021
Outlook Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 37 in the last 12 months · 173 in all · newest Oct 9, 2026 · oldest 2019
- Calls
- 3 calls with a replay · 3 with a transcript · latest Aug 14, 2026
- Decks
- 3 decks · latest Aug 14, 2026
Where Outlook Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:OTLK · Home listing | NASDAQ | United States | USD |
| gettex:41O | gettex | Germany | EUR |
| LS Exchange:A4046T | LS Exchange | Germany | EUR |
| BOATS:OTLK | BOATS | United States | USD |
| Lang & Schwarz:A4046T | Lang & Schwarz | Germany | EUR |
| Tradegate:41O | Tradegate | Germany | EUR |
| Frankfurt:41O | Frankfurt | Germany | EUR |
| Dusseldorf:41O | Dusseldorf | Germany | EUR |
| Hamburg:41O | Hamburg | Germany | EUR |
| Munich:41O | Munich | Germany | EUR |
| Stuttgart:41O · This page | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about Outlook Therapeutics, Inc.